Evidence map›Paper›PMID 39763857›Full record

ArticlebioRxiv : the preprint server for biology2024

BRAF

C Ryland Ill, Nasreen C Marikar, Vu Nguyen, Varuna Nangia, Alicia M Darnell, Matthew G Vander Heiden, Philip Reigan, Sabrina L Spencer

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

C Ryland IllDepartment of Biochemistry, University of Colorado Boulder, Boulder, CO, USA.
Nasreen C MarikarDepartment of Biochemistry, University of Colorado Boulder, Boulder, CO, USA.
Vu NguyenSkaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz, Aurora, CO, USA.
Varuna NangiaDepartment of Biochemistry, University of Colorado Boulder, Boulder, CO, USA.
Alicia M DarnellKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, MA, USA.
Matthew G Vander HeidenKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, MA, USA.ORCID 0000-0002-6702-4192
Philip ReiganSkaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz, Aurora, CO, USA.
Sabrina L SpencerDepartment of Biochemistry, University of Colorado Boulder, Boulder, CO, USA.

Funding

VIRUS PRODUCTION COREP30CA014051 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI Jacqueline A. Lees · 1985 to 2026
$93.9M
Understanding the role of metabolism in cancerR35CA242379 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI VANDER HEIDEN, MATTHEW G. · 2019 to 2025
$5.8M
Opera Phenix High Throughput and High Content Confocal MicroscopeS10OD025072 · OD · UNIVERSITY OF COLORADO · PI LIU, XUEDONG · 2018 to 2018
$1.1M
FACSAria Fusion Cell SorterS10OD021601 · OD · UNIVERSITY OF COLORADO · PI LIU, XUEDONG · 2016 to 2016
$599k
NCI NIH HHS P30 CA014051NCI NIH HHS R35 CA242379NIH HHS S10 OD021601NIH HHS S10 OD025072
6 · The paper itself

Abstract

Targeted kinase inhibitors are well known for their promiscuity and off-target effects. Herein, we define an off-target effect in which several clinical BRAF

Identifiers

PMID39763857
PMCPMC11702603

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.